ODM 201

Drug Profile

ODM 201

Alternative Names: BAY 1841788; ODM-201

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Orion
  • Developer Bayer HealthCare; Orion
  • Class Antineoplastics
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 08 Feb 2017 Phase-III clinical trials in Prostate cancer (Metastatic disease, Combination therapy, First-line therapy) in USA, Belgium, Spain, Finland, Germany and Netherlands before February 2017 (PO) (NCT02799602) (EudraCT2015-002590-38)
  • 08 Feb 2017 Bayer and Orion Pharma plan a phase I drug-drug interaction trial in Healthy volunteers in Germany (PO, Tablet) (NCT03048110)
  • 22 Dec 2016 Translational Research in Oncology and Bayer plan a phase 0 trial in Breast cancer in USA, Canada and Germany (NCT03004534)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top